Fauci on ‘Highly Specific, Direct’ Therapy for COVID-19

Can monoclonal antibodies duplicate the success with Ebola in COVID-19?

by Molly Walker, Associate Editor, MedPage Today
August 28, 2020

Monoclonal antibodies could hold promise in COVID-19 treatment and prevention if the results bear out in clinical trials for efficacy, the nation’s leading infectious diseases expert told MedPage Today.

“There’s a lot of activity and it’s a highly concentrated, highly specific, direct antiviral approach to a number of diseases. The success in Ebola was very encouraging,” said National Institute of Allergy and Infectious Diseases (NIAID) Director Anthony Fauci, MD.

Read full article on MedpageToday.com